Gland Pharma shares rose 2.47% to ₹2,488.20 following the company's announcement of USFDA approval for its generic Sugammadex Injection. According to reports from Business Standard, the approval covers 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials under the company's Abbreviated New Drug Application (ANDA). The approved product is bioequivalent and therapeutically equivalent to Merck Sharp & Dohme's BRIDION Injection.
As reported by Business Standard, the approved product is indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery. According to IQVIA, Sugammadex Injection recorded U.S. sales of about $1.6 billion during the 12 months ended April 2026, highlighting a significant market opportunity. The company has commercially launched the product in the U.S. on the first day of approval through its marketing partner.
According to Business Standard, Gland Pharma is a Hyderabad-based pharmaceutical company focused on generic injectables and ophthalmics that operates in more than 60 countries under a business-to-business model. The company offers a broad portfolio of sterile injectable products, including vials, ampoules, pre-filled syringes, lyophilized vials, infusions, oncology and ophthalmic solutions.
As reported by Business Standard, on a consolidated basis, Gland Pharma's net profit surged 96.57% to ₹366.68 crore while net sales rose 22.31% to ₹1,742.79 crore in Q4 March 2026 over Q4 March 2025. This strong financial performance demonstrates the company's robust operational capabilities in the pharmaceutical sector.
